CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Clinical Trial ID NCT02132624

Rank	Title	Journal	Year	PubWeight™‹?›
1	Engineered T cells: the promise and challenges of cancer immunotherapy.	Nat Rev Cancer	2016	1.51
2	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).	Ther Adv Hematol	2015	0.95
3	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.	Leukemia	2014	0.86
4	Trial Watch: Adoptive cell transfer for oncological indications.	Oncoimmunology	2015	0.84
5	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.	Ther Adv Hematol	2015	0.82
6	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.	World J Stem Cells	2015	0.78
7	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.	Cancer J	2016	0.76
8	Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.	Pediatr Blood Cancer	2015	0.75